Teachers Retirement System of The State of Kentucky Invests $4.27 Million in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Teachers Retirement System of The State of Kentucky purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) in the 3rd quarter, Holdings Channel reports. The fund purchased 100,775 shares of the life sciences company’s stock, valued at approximately $4,268,000.

Several other institutional investors have also modified their holdings of the company. California State Teachers Retirement System grew its position in shares of Integra LifeSciences by 2.1% during the third quarter. California State Teachers Retirement System now owns 96,996 shares of the life sciences company’s stock worth $4,109,000 after acquiring an additional 2,021 shares during the last quarter. Retirement Systems of Alabama grew its position in Integra LifeSciences by 1.0% in the 3rd quarter. Retirement Systems of Alabama now owns 95,110 shares of the life sciences company’s stock valued at $4,029,000 after buying an additional 926 shares in the last quarter. Balyasny Asset Management LLC bought a new position in Integra LifeSciences in the 3rd quarter valued at about $8,984,000. Cooke & Bieler LP grew its position in Integra LifeSciences by 9.6% in the 3rd quarter. Cooke & Bieler LP now owns 2,732,859 shares of the life sciences company’s stock valued at $115,764,000 after buying an additional 239,485 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Integra LifeSciences by 19.4% in the 3rd quarter. Jane Street Group LLC now owns 27,065 shares of the life sciences company’s stock valued at $1,146,000 after buying an additional 4,401 shares in the last quarter. Institutional investors own 87.60% of the company’s stock.

Insider Transactions at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,843 shares of the stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total value of $100,056.47. Following the completion of the sale, the executive vice president now directly owns 28,796 shares of the company’s stock, valued at $1,563,334.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Lisa Evoli sold 3,767 shares of the stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $57.00, for a total value of $214,719.00. Following the completion of the sale, the executive vice president now directly owns 18,605 shares of the company’s stock, valued at $1,060,485. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael J. Mcbreen sold 1,843 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $54.29, for a total transaction of $100,056.47. Following the completion of the sale, the executive vice president now directly owns 28,796 shares of the company’s stock, valued at $1,563,334.84. The disclosure for this sale can be found here. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent analyst reports. Morgan Stanley increased their target price on shares of Integra LifeSciences from $50.00 to $59.00 and gave the company an “equal weight” rating in a research report on Friday, January 6th. StockNews.com initiated coverage on shares of Integra LifeSciences in a research report on Thursday. They issued a “buy” rating for the company. Truist Financial increased their target price on shares of Integra LifeSciences from $52.00 to $58.00 and gave the company a “hold” rating in a research report on Tuesday, December 20th. Citigroup cut their price target on shares of Integra LifeSciences from $60.00 to $59.00 and set a “neutral” rating for the company in a report on Thursday, February 23rd. Finally, TheStreet raised shares of Integra LifeSciences from a “c+” rating to a “b-” rating in a report on Tuesday, December 27th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $58.17.

Integra LifeSciences Price Performance

IART stock opened at $53.44 on Friday. The company has a current ratio of 3.62, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. Integra LifeSciences Holdings Co. has a one year low of $40.67 and a one year high of $67.14. The firm has a market capitalization of $4.36 billion, a PE ratio of 24.74, a P/E/G ratio of 1.51 and a beta of 1.13. The firm has a 50-day moving average of $56.54 and a two-hundred day moving average of $52.35.

Integra LifeSciences (NASDAQ:IART – Get Rating) last posted its quarterly earnings data on Wednesday, February 22nd. The life sciences company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.01. Integra LifeSciences had a net margin of 11.59% and a return on equity of 16.51%. The company had revenue of $398.00 million during the quarter, compared to analyst estimates of $398.57 million. During the same period in the prior year, the firm earned $0.84 earnings per share. The business’s quarterly revenue was down 1.8% on a year-over-year basis. On average, analysts forecast that Integra LifeSciences Holdings Co. will post 3.48 earnings per share for the current year.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.